Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
652206
Reference Type
Journal Article
Title
Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists
Author(s)
Bullock, CM; Li, JD; Zhou, QY
Year
2004
Is Peer Reviewed?
1
Journal
Molecular Pharmacology
ISSN:
0026-895X
EISSN:
1521-0111
Volume
65
Issue
3
Page Numbers
582-588
Language
English
DOI
10.1124/mol.65.3.582
Abstract
Prokineticins are cysteine-rich secreted proteins that regulate diverse biological processes, including gastrointestinal motility, angiogenesis, and circadian rhythms. Two closely related G protein-coupled receptors that mediate signal transduction of prokineticins have recently been cloned. The structural elements required for prokineticins' bioactivities are still unknown. We show here that both the N-terminal hexapeptide (AVITGA) and C-terminal cysteine-rich domains are critical for the bioactivities of prokineticins. Substitutions, deletions, and insertions to the conserved N-terminal hexapeptides result in the loss of agonist activity. Mutant prokineticins with the substitution of the first N-terminal alanine with methionine or the addition of a methionine to the N terminus inhibit the activation of prokineticin receptors and thus are considered as antagonists of prokineticin receptors. We have further shown that mutations in selected cysteine residues in the C-terminal domain result in prokineticins without biological activity. The essential role of C-terminal domain is reinforced by two observations: that peptides without the carboxyl domain and proteins with the N-terminal hexapeptide fused to the carboxyl domains of colipase or dickkopf are devoid of biological activity. We demonstrate that limited structural changes of C-terminal cysteine-rich regions of prokineticins are tolerable because chimeric prokineticins with swapped cysteine-rich domains between prokineticin 1 and prokineticin 2, as well as a splice variant of prokineticin 2 that contains extra 21 residue insertion in its C-terminal domain, are biologically active.
Keywords
*Alternative Splicing; Animals; CHO Cells; Carrier Proteins/chemistry/metabolism; Cricetinae; Cysteine/chemistry; Gastrointestinal Hormones/chemistry/genetics/*metabolism; Mutagenesis, Site-Directed; Neuropeptides/chemistry/drug effects/genetics/*metabolism; Peptide Fragments/chemistry/genetics/metabolism/pharmacology; Protein Structure, Tertiary; Recombinant Fusion Proteins/chemistry/*metabolism
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity